BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diagnostics (Basel)
Autori principali: Bilbao-Sieyro, Cristina, Rodríguez-Medina, Carlos, Florido, Yanira, Stuckey, Ruth, Sáez, María Nieves, Sánchez-Sosa, Santiago, González Martín, Jesús María, Santana, Guillermo, González-Pérez, Elena, Cruz-Cruz, Naylén, Fernández, Rosa, Molero Labarta, Teresa, Gomez-Casares, María Teresa
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7762084/
https://ncbi.nlm.nih.gov/pubmed/33291851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10121048
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi